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ABSTRACT 
Central diabetes insipidus (DI) is well documented as a presenting feature of 
myelodysplastic syndrome and acute myeloid leukemia in adults. However, DI is 
unusual in pediatric patients with myeloid malignancies. We report here this rare 
complication in a child with neurofibromatosis type 1 who developed juvenile 
myelomonocytic leukemia and monosomy 7. Our case and previously reported 
cases of DI arising as a complication in myeloid malignancies demonstrate a 
close association with deletion of chromosome 7. The clinical characteristics and 
outcomes of these uncommon cases in children are reviewed and discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloid malignancy 
of childhood. This disorder is currently classified under myelodysplastic/ 
myeloproliferative neoplasms (MDS/MPN) in children by the World Health 
Organization (WHO) [1]. Hepatosplenomegaly, lymphadenopathy, and 
constitutional symptoms are the most common presenting features [2]. Even 
though central DI had been described in association with other myeloid 
malignancies of adults, it is rare in JMML. Niemeyer et al [2] described only one 
case with DI in a retrospective study of 110 JMML cases. Hasle et al [3] reported 
43 JMML cases with monosomy 7 and two of them presented with DI. A review 
of previous local data of 21 JMML patients in Hong Kong showed that 3 of them 
had monosomy 7 but none of them was complicated with DI (Chan GCF, 
unpublished data). We describe here our first case of JMML patient with 
neurofibromatosis type 1 (NF1) and monosomy 7 who was complicated by 
central DI, and compare the clinical and laboratory features with those in the 
literature. 
 
CASE REPORT 
A previously healthy 8-year-old Indonesian girl was found to have leucocytosis, 
monocytosis, and mild anemia during an episode of acute diarrhea. An initial 
bone marrow study revealed increased myelomonocytic series which was 
compatible with a myeloproliferative disorder. A diagnosis of JMML was 
suspected. In the subsequent two months, she complained of progressive 
abdominal distension, polydipsia and polyuria. She was admitted into hospital in 
a semi-comatose state with dehydration. A complete blood count showed marked 
leukocytosis of 90 x 109/L, with hemoglobin (Hb) 9.9 g/dL and platelet count 79 x 
109/L. After rehydration, she received one course of cytarabine and etoposide 
(100 mg/m2/day intravenous infusion for each) for 5 days, followed by low dose 
cytarabine (20 mg/m2/day) for 5 days. Her condition stabilized and she was 
transferred to our center for further workup. On admission, she was found to 
have multiple café-au-lait spots (>6 and each >5 mm in greatest diameter) and 
hepatosplenomegaly. The patient's mother had multiple café-au-lait macules and 
scattered neurofibromas consistent with NF1. The clinical findings of café au lait 
macules and NF1 in a first-degree relative established the diagnosis of NF1 in 
our patient [4]. Repeated peripheral blood examination showed a 
leucoerythroblastic picture, with Hb 10.7 g/L, white blood cell count 23.6 x 109/L 
(monocyte 31%, blast 7%), and platelet count 56 x 109/L. Her Hb F was 1%. 
Repeated bone marrow examination revealed active granulopoiesis and 
dysplastic megakaryocytes. Marrow blast count was 18%. Cytogenetic analysis 
showed monosomy 7 (Fig. 1A). Utilizing fluorescence in situ hybridization, 
monosomy 7 was demonstrated in 88.5% of the marrow nucleated cells (Fig. 
1B). The cerebral spinal fluid examination was unremarkable. Anterior pituitary 
function testing was normal. Magnetic resonance imaging (MRI) of the brain 
showed absence of a normal bright spot over the posterior pituitary gland without 
thickening of the pituitary stalk (Fig. 1C and D). Central DI was subsequently 
confirmed by biochemical and imaging studies. A diagnosis of central DI 
complicating JMML with monosomy 7 in a patient with NF1 was made, according 
to the WHO Classification [1]. Her polyuria resolved dramatically after 
commencing desmopressin (DDAVP). The patient was returned to her referring 
pediatrician, pending for an appropriate donor for hematopoietic stem cell 
transplantation (HSCT).  
 
DISCUSSION 
The association of central DI and myeloid malignancies has been uncommonly 
reported, even though peri-hypophyseal leukemic infiltrates were found in 46% of 
adult patients with acute leukemia at postmortem [5]. The onset of DI is variable, 
but usually occurs as a presenting feature of the myeloid malignancies [6]. The 
possible mechanisms include leukemic infiltration, leukostasis, thrombosis, 
fibrosis, infection, and hemorrhage in the hypothalamo-neurohypophyseal system 
[7]. In most patients the MRI findings are normal. Classical finding of 
disappearance of the physiological hyperintense signal, termed “bright spot”, at 
the neurohypophysis is caused by the loss of the vasopressin-containing vesicles 
in the posterior pituitary. Thickened infundibulum is also seen in some reported 
cases [6,7]. Loss of the bright spot at the posterior pituitary has been suggested 
to be related to leukemic infiltration.  
 
Of note, cases of acute myeloid leukemia (AML)/MDS complicated by DI have 
been reported to be associated with abnormalities of chromosome 7 [monosomy 
7 or del(7q)] and/or chromosome 3 [inv(3)(q21q26) or t(3;3)(q21;q26)] [6-8]. 
Cytogenetic analysis also revealed monosomy 7 in our JMML patient, again 
supporting the postulation that this karyotypic change is one factor contributing to 
the development of DI. For patients with partial or complete monosomy 7, the 
neutrophil migration gene in 7q22~qter region is lost, which increases 
susceptibility to infection and may predispose patients to onset of DI [9]. 
Moreover, because most circulating arginine vasopressin (ADH) is bound to the 
platelets, thrombocytosis related to dysthrombopoiesis in monosomy 7 and/or 
3q21q26 syndrome may interfere with level and function of circulating ADH [10].  
  
Review of the English literature of pediatric myeloid malignancies and DI yielded 
nine cases (Table 1) [11-19]. Seven of these (78%) patients had DI at diagnosis 
of AML/MDS. Cytogenetic data were available in four patients, of whom 
monosomy 7 and/or inversion of chromosome 3 was most commonly detected. 
Two patients had AML/MDS associated with NF1 and monosomy 7. Imaging 
studies were performed in five patients and only one patient had loss of pituitary 
bright spot and enhancement of infundibulum. Two of three patients, who 
underwent postmortem examination, had leukemic infiltration in the posterior 
pituitary and one patient had suspected destruction of the hypothalamic nuclei by 
either infarction or arachnoid infiltration. Only two of the nine patients (22%) 
achieved disease remission with resolution of DI. Interestingly, Harb et al [6] also 
found that reported cases of AML complicated by DI with monosomy 7 (n = 25) 
had a trend towards lower complete remission (CR) and survival rates than those 
with other chromosomal aberrations (n = 6). Furthermore, AML cases with 
monosomy 7 and DI had worse CR rate than AML with monosomy 7 but without 
DI.  
 
In conclusion, DI is a rare but important complication of myeloid malignancies in 
both adults and children and tends to occur early in the disease course. It is 
closely associated with the karyotypic abnormality of monosomy 7. The 
pathophysiological link between DI and monosomy 7 is unclear. Whether the 
complication of DI has additional poor prognostic implication is difficult to assess 
because of the rarity of such cases and the inherent poor prognosis of myeloid 
malignancies associated with monosomy 7 or 3q21q26 rearrangement. 
Nevertheless, it is important to recognize this unique complication in pediatric 
patients with myeloid malignancies and provide timely supportive treatment to 
prevent dehydration, electrolyte disturbances and aggravation of leukostasis-
related complications.   
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Fig. 1. A: Karyotype showing monosomy 7 (arrow; G-banding with trypsin-
Giemsa). B: Fluorescence in situ hybridization analysis of interphase cells using 
centromeric probe for chromosome 7, showing the presence of monosomy 7 that 
appears as single distinct red fluorescence signal within marrow cells. C: Sagittal, 
T1-weighted magnetic resonance (MRI) image, representing disappearance of 
the physiological signal („„bright spot‟‟) of the posterior pituitary (arrow). D: 
Coronal T1-weighted MRI image after gadolinium, disclosing normal sized 
pituitary stalk (arrow) and no enhancing lesion of hypothalamus and posterior 
pituitary. 
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TABLE 1. Literature Review of diabetes insipidus in associated with childhood myeloid malignancies.  
 
 
Reference 
 
Age (years)/ 
Gender 
Type of myeloid 
malignancies 
Cytogenetics 
Onset of DI,  
from diagnosis 
Imaging Outcome 
Survival 
from 
diagnosis 
Histopathology of 
hypothalamus 
and 
neurohypophysis  
Joseph et al, 
1956 [11] 
10/ male AML 
 
NA At diagnosis NA Died of 
disease 
progression 
2 months Leukemic 
infiltration in 
posterior pituitary 
Roy et al, 
1970 [12] 
3.5/ male AML 
(FAB-M6) 
NA 4 months NA 
 
Died of 
infection 
 
6 months Leukemic 
infiltration in 
pituitary stalk 
Bergman et al, 
1976 [13] 
8/ female 
 
AML 
 
NA 
 
At diagnosis 
 
NA 
 
Died of 
disease 
relapse 
3 months Areas of gliosis 
and hemosiderin 
pigment containing 
in hypothalamus 
and posterior 
pituitary 
Betkerur et al, 
1977 [14] 
9/ female 
 
AML NA 
 
At diagnosis NA Died of 
disease 
progression 
2 months NA 
Kanabar et al, 
1994 [15] 
7/ male 
 
AML 
(FAB-M2) 
Monosomy 7 At diagnosis normal
a
 No CR after 
three 
courses of 
induction 
NA NA 
Diltek et al,  
1998 [16] 
16/ male AML 
(FAB-M4) 
NA At diagnosis normal
a
 Died of 
bleeding 
2 days NA 
Frangoul et al,  
2000 [17] 
11/ male AML 
(FAB-M2) 
47, XXY At diagnosis No bright spot,
 
thickened and 
enhancing 
pituitary stalk
b
 
Alive, in 
remission 
after CMT 
NA NA 
Wössmann     
et al,  2002 [18] 
11/ male AML 
(FAB-M7) 
45, XY, 
inv(3)(q21q26), –7 
At diagnosis normal
b
 Died of 
infection in 
post-HSCT 
10 months 
 
NA 
Kollen et al,  
2003 [19] 
6/ male MDS 
(RAEB) 
Monosomy 7 6 months normal
b
 Alive, in 
remission 
after HSCT 
NA NA 
a, computed tomography of brain. b, magnetic resonance imaging of brain 
AML, acute myeloid leukemia; FAB, French American British grouping; CMT, chemotherapy; CR, complete remission; DI, diabetes insipidus; HSCT, hematopoietic stem cell 
transplantation; MDS, myelodysplastic syndrome; NA, not applicable; RAEB, refractory anemia with excessive blasts. 
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